Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IART declined for three days, in 233 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IART as a result. In 69 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for IART turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
The Aroon Indicator for IART entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for IART's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 181 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IART may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.883) is normal, around the industry mean (2.923). P/E Ratio (-131.556) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IART’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RVTY advanced for three days, in 199 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RVTY as a result. In 59 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 110 of 181 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 67 cases where RVTY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.418) is normal, around the industry mean (64.450). P/E Ratio (75.293) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
IART | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 86 | |
PRICE GROWTH RATING 1..100 | 62 | 3 | |
P/E GROWTH RATING 1..100 | 14 | 6 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IART's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for RVTY (79). This means that IART’s stock grew significantly faster than RVTY’s over the last 12 months.
IART's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RVTY (100). This means that IART’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's SMR Rating (86) in the Medical Specialties industry is in the same range as IART (91). This means that RVTY’s stock grew similarly to IART’s over the last 12 months.
RVTY's Price Growth Rating (3) in the Medical Specialties industry is somewhat better than the same rating for IART (62). This means that RVTY’s stock grew somewhat faster than IART’s over the last 12 months.
RVTY's P/E Growth Rating (6) in the Medical Specialties industry is in the same range as IART (14). This means that RVTY’s stock grew similarly to IART’s over the last 12 months.
| IART | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 66% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 68% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 65% |
| Advances ODDS (%) | 11 days ago 62% | 2 days ago 67% |
| Declines ODDS (%) | 2 days ago 78% | 4 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 69% | N/A |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 61% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IART’s FA Score shows that 2 FA rating(s) are green while RVTY’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IART’s TA Score shows that 4 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s).
IART (@Medical/Nursing Services) experienced а -10.13% price change this week, while RVTY (@Medical Specialties) price change was +2.95% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.58%. For the same industry, the average monthly price growth was -10.79%, and the average quarterly price growth was -10.51%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
IART is expected to report earnings on Mar 03, 2027.
RVTY is expected to report earnings on Nov 03, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, IART has been loosely correlated with RVTY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if IART jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To IART | 1D Price Change % | ||
|---|---|---|---|---|
| IART | 100% | -11.18% | ||
| RVTY - IART | 49% Loosely correlated | +0.38% | ||
| CNMD - IART | 48% Loosely correlated | -0.99% | ||
| MTD - IART | 44% Loosely correlated | +2.69% | ||
| A - IART | 43% Loosely correlated | +2.74% | ||
| AZTA - IART | 43% Loosely correlated | +2.88% | ||
More | ||||